This is a working overview of thymosin beta-4, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-07-17 and is reviewed periodically as new material appears.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.
Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.
| Property | Value | Notes |
|---|---|---|
| Reported sequence | Ac-LKKTETQ | Described in most listings as the actin-binding region of thymosin beta-4 |
| Reported molecular weight | Approximately 889 Da | Value shifts with the stated sequence; compare against the certificate of analysis |
| Parent protein length | 43 amino acids | Thymosin beta-4; the fragment covers only a small part of it |
| Common synonyms | TB4 fragment; thymosin beta-4 fragment | Trade-style names rather than formal nomenclature |
| Formal monographs | Not established | Labeling conventions differ by supplier and region |
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
=== Wound healing and fibrosis === In skin wound healing, CCN1 is highly expressed in the granulation tissue by myofibroblasts, which proliferate and rapidly synthesize ECM to maintain tissue integrity and to promote regeneration of parenchymal cells. However, excessive matrix deposition can lead to fibrosis, scarring, and loss of tissue function. In skin wounds, CCN1 accumulates in the granulation tissue as myofibroblasts proliferate, and eventually reaches a sufficiently high level to drive the myofibroblasts themselves into senescence, whereupon these cells cease to proliferate and express matrix-degrading enzymes. Thus, CCN1 limits synthesis and deposition of ECM by myofibroblasts, reducing the risk of fibrosis during wound healing. In addition to skin wound healing, CCN1 expression is elevated in remodeling cardiomyocytes after myocardial infarction, in vascular injury, and in the long bones during fracture repair. Blockade of CCN1 by antibodies inhibits bone fracture healing in mice. In the kidney, CCN1 is expressed in podocytes in normal adult and embryonic glomeruli, but expression is decreased in IgA nephropathy, diabetic nephropathy, and membranous nephropathy, particularly in diseased kidneys with severe mesangial expansion. CYR61 induction of cellular senescence in the kidney is a potential therapy to limit fibrosis.
=== Tut's Egyptian Street Food === Tut's is a Canadian fast-casual restaurant chain that specializes in Egyptian street food, particularly sandwiches. The business was established in August 2020 with a flagship location in Downtown Toronto and has since expanded to multiple locations across Ontario. Tut's menu features modern adaptations of traditional Egyptian recipes, presented in a quick-service format.
When ice crystals are aligned with their basal planes parallel to the temperature gradient (z-crystals), they can be represented as two resistors in parallel. The thermal resistance of the ceramic is significantly smaller than that of the ice however, so the apparent resistance can be expressed as the lower Rceramic. If the ice crystals are aligned perpendicular to the temperature gradient (r-crystals), they can be approximated as two resistor elements in series. For this case, the Rice is limiting and will dictate the localized thermal conditions. The lower thermal resistance for the z-crystal case leads to lower temperatures and greater heat flux at the growing crystals tips, driving further growth in this direction while, at the same time, the large Rice value hinders the growth of the r-crystals. Each ice crystal growing within the slurry will be some combination of these two scenarios. Thermodynamics dictate that all crystals will tend to align with the preferential temperature gradient causing r-crystals to eventually give way to z-crystals, which can be seen from the following radiographs taken within the TZ. When z-crystals become the only significant crystal orientation present, the ice-front grows in a steady-state manner except there are no significant changes to the system conditions. It was observed in 2012 that, in the initial moments of freezing, there are dendritic r-crystals that grow 5 - 15 times faster than the solidifying front. These shoot up into the suspension ahead of the main ice front and partially melt back.
Sources: en.wikipedia.org
In Australia, diamorphine is listed as a schedule 9 prohibited substance under the Poisons Standard (October 2015). The state of Western Australia, in its Poisons Act 1964 (Reprint 6: amendments as at 10 September 2004), described a schedule 9 drug as: "Poisons that are drugs of abuse, the manufacture, possession, sale or use of which should be prohibited by law except for amounts which may be necessary for educational, experimental or research purposes conducted with the approval of the Governor."
=== Early work === Thomson's prize-winning master's work, Treatise on the motion of vortex rings, shows his early interest in atomic structure. In it, Thomson mathematically described the motions of Lord Kelvin's vortex theory of the atom. Thomson published a number of papers addressing both mathematical and experimental issues of electromagnetism. He examined the electromagnetic theory of light of James Clerk Maxwell, introduced the concept of electromagnetic mass of a charged particle, and demonstrated that a moving charged body would apparently increase in mass. Much of his work in mathematical modelling of chemical processes can be thought of as early computational chemistry. In further work, published in book form as Applications of dynamics to physics and chemistry (1888), Thomson addressed the transformation of energy in mathematical and theoretical terms, suggesting that all energy might be kinetic. His next book, Notes on recent researches in electricity and magnetism (1893), built upon Maxwell's Treatise upon electricity and magnetism, and was sometimes referred to as "the third volume of Maxwell." In it, Thomson emphasized physical methods and experimentation and included extensive figures and diagrams of apparatus, including a number for the passage of electricity through gases. His third book, Elements of the mathematical theory of electricity and magnetism (1895) was a readable introduction to a wide variety of subjects, and achieved considerable popularity as a textbook.
== The Beer Week Seoul == The Booth hosts one of the biggest craft beer events in Korea, the Beer Week Seoul. The event introduces breweries and sells beers normally unavailable to the Korean market. Breweries such as Other Half, Mikkeller, Evil Twin, To Øl, and AleSmith have participated in the past. The Booth's flagship beer, Kukmin IPA, was awarded Best Craft Beer at the 2017 Korea Wine and Spirits Awards. Two of the co-founders, Heeyoon Kim and Sunghoo Yang, were selected for Forbes 30 Under 30 Asia for 2017.
Sources: en.wikipedia.org
=== Components of the library form in equal molar quantities === As far as the chemistry of the couplings makes it possible the components of the libraries form in nearly equal molar quantity. This is made possible by dividing of the mixtures into equal samples and by homogenization of the pooled samples by thoroughly mixing them. The equal molar quantity of components of the library is very important considering their applicability. The presence of compounds in unequal quantities may lead to difficulties in evaluation of the results in screening. The solid phase method makes it possible to use the reagents in excess to drive the reactions close to completion since the surplus can easily be removed by filtration.
The group had to overcome initial bureaucratic reluctance to pursue sertraline development, as Pfizer was considering licensing an antidepressant candidate from another company. Sertraline was approved by the US Food and Drug Administration (FDA) in 1991 based on the recommendation of the Psychopharmacological Drugs Advisory Committee; it had already become available in the United Kingdom the previous year. The FDA committee achieved a consensus that sertraline was safe and effective for the treatment of major depression. During the discussion, Paul Leber, the director of the FDA Division of Neuropharmacological Drug Products, noted that granting approval was a "tough decision", since the treatment effect on outpatients with depression had been "modest to minimal". Other experts emphasized that the drug's effect on inpatients had not differed from placebo and criticized the poor design of the clinical trials by Pfizer. For example, 40% of participants dropped out of the trials, significantly decreasing their validity. Until 2002, sertraline was only approved for use in adults ages 18 and over; that year, it was approved by the FDA for use in treating children aged 6 or older with severe OCD. In 2003, the UK Medicines and Healthcare products Regulatory Agency issued guidance that, apart from fluoxetine (Prozac), SSRIs are not suitable for the treatment of depression in patients under 18. However, sertraline can still be used in the UK for the treatment of OCD in children and adolescents.
=== Melanoma === For high-risk melanoma, it is used as an adjuvant therapy to surgery in some countries. It was first approved for the purpose by FDA on 29 March 2011, based on a single phase III trial. The usage remains controversial — frequency of severe side-effects is high, overall survival benefits substantially vary across different trials, and there is no consensus on the dosage regimen. Meta-analyses have suggested that the drug might be more helpful for patients with ulcerated primary lesion.
The CDC has also expanded its Get Ahead of Sepsis campaign in 2023, focusing on raising awareness of AMR's role in sepsis and promoting the judicious use of antibiotics in both healthcare and community settings. This initiative has reached millions through social media, healthcare facilities, and public health outreach, aiming to educate the public on the importance of preventing infections and reducing antibiotic misuse. Under the administration of Donald J. Trump, severe federal funding cuts in 2025 at the National Institutes of Health (NIH) and many other research entities in the United States are expected to impede progress in combating antimicrobial resistance. Public health experts believe these budget reductions will adversely affect the development of new antibiotics as well as advances in diagnostics and treatment strategies, thus undermining efforts currently underway to address AMR. The Infectious Diseases Society of America (IDSA) is but one organization that has expressed grave concern regarding the negative consequences of such extreme budget measures on antimicrobial stewardship, and, as a result, on global health security overall.
Sources: en.wikipedia.org
Most listings describe it as a short acetylated peptide with the sequence Ac-LKKTETQ, presented as a region of thymosin beta-4. The label is a trade-style name rather than a standardized chemical name, so the exact content of a given vial depends on the supplier.
No. Thymosin beta-4 is a protein of 43 amino acids, while TB-500 is described as a short fragment of it. The two differ in size, structure, and the range of interactions each can support.
Naming for research peptides is not centrally coordinated, so vendors set their own labels and specifications. Differences in stated sequence, molecular weight, or purity documentation usually trace back to those independent labeling choices.
The most common approach is liquid chromatography with tandem mass spectrometry after extraction from blood or urine. Immunoassays exist but are generally treated as screening tools because of cross-reactivity.